Thank you. Earlier today, Seer released financial results for the quarter ended September 30, 2024. If you've not received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to [email protected]. Joining me today from Seer is Omid Farokhzad, Chief Executive Officer and Chair; and David Horn, Chief Financial Officer and President. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Seer issued today. For a more complete list and description, please see the Risk Factors section of the company's quarterly report on Form 10-Q for the quarter ended September 30, 2024, and its other filings with the Securities and Exchange Commission. Except as required by law, Seer disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, November 6, 2024. With that, I'll turn the call over to Omid.

Thanks, Carrie, and thank you, everyone, for joining us this afternoon. I will begin our call today by providing updates on our business, and I will then turn the call over to David to provide more detail on our financial results for the third quarter of 2024 and our outlook for the remainder of the year. We continue to see growing enthusiasm for the Proteograph Product Suite during the third quarter despite the ongoing macro environment pressures, especially for the adoption of new technology. We ended the third quarter with $4 million in revenue and approximately $312 million in cash, cash equivalents, and investments. In particular, we were pleased to see multiple large orders from government agencies and continued strong interest in our STAC. While the capital purchasing environment remains challenging and a continuous headwind for us, we believe we're starting to see the flywheel effect and an increasing tailwind that comes with a growing number of customer publications and preprints highlighting the value of the Proteograph. In the near term, we expect to see fluctuations in the relative strength of these two vectors. That said, I'm confident that directionally, we're picking up momentum as the data and evidence is strongly supportive of Proteograph's unique value proposition. At Seer, we're continuing to push the boundaries of what is possible to provide access to large-scale deep unbiased proteomics and help researchers generate meaningful insights into human health and disease. To that end, we're delighted that Thermo Fisher Scientific, the leading mass spectrometry provider, is partnering with Seer, a pioneer and leader in proteomics, to co-market and sell the Proteograph Product Suite alongside their Orbitrap Astral mass spectrometers. Under this non-exclusive agreement starting in early 2025, Thermo Fisher's global sales force will have the ability to quote and sell the Proteograph Product Suite, which includes an automation instrument, proprietary engineered nanoparticles, and software analysis suite, enhancing the accessibility of this innovative technology to life science researchers worldwide. We believe Thermo Fisher's Orbitrap Astral sets the gold standard for mass spectrometry. The robustness and performance of the Sphere platform and the sensitivity of the Orbitrap Astral make it possible for the first time to do population scale, deep unbiased proteomics with unprecedented power to drive biological insights. Last year, we collaborated with Thermo Fisher to exclusively use their Orbitrap Astral in our Seer Technology Access Center in the U.S. And earlier this year, we expanded the program to Europe. We have seen firsthand the highly differentiated and exceptional data that our customers are getting by working with our STAC as well as the exceptional results from a growing number of customers who are using the Orbitrap Astral and the Proteograph Product Suite in their own labs. This new collaboration makes it possible for customers to acquire the Proteograph Product Suite in conjunction with the acquisition of the Orbitrap Astral. We will also conduct joint marketing initiatives, including conference promotions, seminars and webinars and collaborate on joint research studies, including population scale studies to showcase the combined power of the proteomics platforms. We're excited by the expanded geographic reach and distribution that this partnership with Thermo Fisher will provide. By aligning our technologies, we're providing researchers with a robust solution that enables comprehensive proteomic insights, ultimately driving breakthroughs in understanding human biology and disease. We continue to serve customers through the Seer Technology Access Center, or STAC, which allows a Proteograph user to run samples in their own lab and have Seer run the mass spec or alternatively, provide end-to-end study services from sample to data. We continue to see strong demand for STAC and have a strong pipeline heading into the end of the year despite continuing to navigate a challenging funding environment. STAC has been successful in enhancing access to the Proteograph and bringing the power of unbiased proteomics data to a growing number of researchers. We believe this increased access will catalyze the generation of third-party data and publications, further highlighting the transformative potential of our technology and facilitating broader adoption. Earlier this year, we launched a second STAC lab in Germany, and we're excited to see increasing demand from prominent researchers in Europe that want to access the unique data that the Proteograph provides. We continue to see STAC as a strategic asset to invest in groundbreaking studies and run large sample cohorts for key collaborators, providing STAC services at lower price points. We expect these customers will present and publish their studies shortly, further reinforcing the differentiated value proposition of the Proteograph Product Suite and serve as key reference to drive continued adoption of our technology. In addition, we're seeing traction with our Strategic Instrument Placement program, or SIP, which continues to be an important catalyst for adoption, particularly for large pharma customers, many of which have purchased instruments through this program. Now moving to the exemplification of our technology. We continue to see a growing number of preprints and publications showcasing the value of the Proteograph Product Suite. Notably, our conversations with potential customers are becoming increasingly productive as more researchers see the value and insights our data provides, and we're seeing the scale of projects getting larger. We had a strong presence at the 23rd Human Proteome Organization, or HUPO World Congress in Germany in late October, where our customers, collaborators and Seer scientists showcased a total of 12 posters and oral presentations. This research revealed new insights into Alzheimer's pathways, population scale plasma analysis, and captured immune dynamics in xenotransplantation. One of our collaborators, Dr. Mike Snyder from Stanford University, presented data that highlighted the value of the Proteograph Product Suite for deep proteomic analysis in model organisms. In collaboration with Seer, Dr. Snyder and his team are conducting an aging study in a nonhuman primate model, specifically in pig-tailed macaques. In this study, 230 monkey plasma samples and 25 human plasma samples were analyzed using the Proteograph XT coupled with the Orbitrap Astral. A total of 8,472 unique protein groups were identified across the 230 monkey plasma samples. As a comparison, the Proteograph assay identified 11 times more protein groups in this cohort versus direct digestion workflow using the Orbitrap Astral alone without the Proteograph. Combined with the depth of proteomic coverage and the protein and peptide level resolution that the Seer platform provides, they're now able to investigate shared and species-specific human and macaque biology in a deep and unbiased manner. While they're early in their analysis, they're encouraged by the types of protein biomarkers differentially expressed in male versus female monkeys and across various age groups in the monkey cohort. For example, they have found many interesting biological differences in cytokines or hormones and immune response-related proteins, which can be difficult to detect due to the low abundance in plasma samples. This is yet another example of the power of the Proteograph to enable unbiased deep proteomics that reveal interesting insights and pathways for further study in nonhuman primate models. I remain incredibly optimistic about the long-term value of our differentiated technology and its potential to transform our understanding of the proteome. Looking ahead, we will continue to execute against our core strategies of driving evidence and publications, continuing to enhance access to the Proteograph, innovate with our products and expand our applications. With that, I will now turn the call over to David.

Thanks, Omid. Total revenue for the third quarter of 2024 was $4 million, representing a decrease of 3% compared to $4.2 million in the third quarter of 2023 and was primarily due to a decrease in related party revenue and grant revenue recognized in the quarter. Revenue recognized primarily consisted of sales of the Proteograph SP100 instruments, consumable kits and service revenue, of which $366,000 was attributed to related parties. Product revenue for the third quarter of 2024 was $3.1 million, including $180,000 of related party revenue and consisted of sales of SP100 instruments and consumable kits. Product revenue grew year-over-year, primarily driven by an increase in instrument sales and consumable kit sales. Despite seeing continued pressure on CapEx budget and elongated sales cycles for the outright purchase of new instrumentation in the third quarter, we were encouraged by signs of a more constructive capital purchasing environment. Service revenue was $847,000 in the third quarter of 2024, including $186,000 of related party revenue and primarily consisted of revenue related to STAC service projects. We continue to be encouraged by the customer interest in running projects through STAC and their ability to gain access to Proteograph data. We also continue to undertake projects for key strategic studies that will result in additional presentations and publications in the near term, but are conducted at a lower price point than our typical STAC service projects. This had the effect of lowering the amount of service revenue that was realized in the third quarter. Grant and other revenue was $90,000 for the third quarter of 2024 and consisted of lease and shipping revenue. Total gross profit was $1.9 million for the third quarter of 2024, representing a gross margin of 48%, compared to $2.2 million in the third quarter of 2023, representing a gross margin of 52%. Gross margins were driven by higher instrument sales and lack of grant revenue in the third quarter of 2024 relative to the third quarter of 2023. We continue to expect variability in our gross margin on a quarter-by-quarter basis since the proportion of instrument consumable and service revenue will fluctuate in any given quarter. Total operating expenses for the third quarter of 2024 were $26.3 million, including $6.1 million of stock-based compensation, a decrease of 6% compared to $28 million, including $7.9 million of stock-based compensation in the third quarter of 2023. Research and development expenses for the third quarter of 2024 were $13 million, a decrease of 2% compared to $13.2 million in the third quarter of 2023. The decrease in R&D expenses was primarily due to a decrease in employee and stock-based compensation expenses. Selling, general and administrative expenses for the third quarter of 2024 were $13.3 million, a decrease of 10% compared to $14.8 million in the third quarter of 2023. The decrease in SG&A expenses was primarily due to a decrease in employee and stock-based compensation expenses. Net loss for the third quarter of 2024 was $21.3 million compared to $21.1 million in the third quarter of 2023. We ended the quarter with approximately $312 million in cash, cash equivalents, and investments. During the third quarter, we invested $10 million in PrognomiQ Series D financing alongside other existing investors and a new large strategic investor. As previously announced, our Board of Directors authorized a $25 million share repurchase program in May of this year. Under this program, we repurchased approximately 3.7 million shares of Seer Class A common stock at an average cost of $1.78 per share during the third quarter. As of September 30, we had approximately $14.7 million in authorization remaining under this share repurchase program. Free cash flow loss was approximately $39 million for the nine months ended September 30, 2024. And as previously stated, we estimate that our 2024 free cash flow loss will be less than our free cash flow loss in 2023. Turning to our outlook for the year. We continue to expect revenue to be in the range of $13 million to $15 million for 2024. At this point, I would like to turn the call back to Omid for closing comments.

Thank you, David. I'd like to thank our incredible team for their hard work this quarter as we continue navigating through a challenging macro environment for the adoption of new technology. We have made solid progress on a number of initiatives that we established to enhance access to the Proteograph Product Suite and assist our customers in generating novel data. Looking ahead, we believe these initiatives position us well for growth in 2025 and beyond. I look forward to keeping you updated on our progress. With that, we will now open it up to questions. Operator?

Our first question comes from Yuko Oku with Morgan Stanley.

This is Jason on for Yuko. So maybe just starting off, given the midpoint of your 2024 guide of $14 million, it seems to imply a flat or slightly negative sequential step-down from 3Q to 4Q, which seems to break with the 4Q seasonality trends for your company in the past few years. So maybe can you talk a bit about your assumptions surrounding this? So is it mostly conservatism? And what are your assumptions surrounding the budget flush dynamic?

Yes, regarding the guidance, given our current position in the quarter, we have several opportunities in our pipeline. It mainly depends on the timing of these deals. If they progress in our favor, we would expect to be at the higher end of our range. However, if some are delayed, the outcome will change. So, it all hinges on our current situation and the timing of various factors, along with our revenue base, which could go either way. We're aiming to maintain our range, depending on when the deals close. We also continue to observe pressure on budgets, so we are not anticipating a budget boost for the fourth quarter. That's just our perspective based on where we are at the moment.

And then maybe as a follow-up question. During 2Q, you talked about significantly expanding your sales and marketing team to include the addition of multiple new regional sales managers. So did that initiative drive the beat at all? If it hasn't, then presumably it might take some time to ramp up. So when can you expect benefits from this initiative to flow through to the P&L?

As we mentioned at the last earnings call, we had significantly expanded the sales and marketing team. We have added multiple new regional business managers. We had added our new VP of Global Marketing, Zach Crowther, to the team. Now these new team members are ramping up. They're already making good progress. We feel very good about the opportunities that they're creating, getting us to the end of the year and into 2025. I think the additional build that we did to the team was just the right move and the benefit of it, we should be seeing later this year and into 2025.

And then maybe if I could just sneak one more in. So I think you've also previously commented on your sales channel kind of flipping from a 60-40 mix of commercial and academic historically to now being 60-40 academic and commercial. So I was wondering what's kind of driving the shift towards academic customers? Like how much would you attribute this shift to benefits from the cadence of publications that you have seen to date versus headwinds and capital constraints from larger biopharma customers who are maybe like announcing strategic shifts or pruning their portfolio?

Let me take a crack at it, and maybe I'll also have David comment on the back end of it, if I leave anything out. So our pipeline of customer and the closed accounts, meaning customers that we actually close, that's different. So we're seeing more and more academic folks end up in our pipeline of customers. And as I mentioned, an increasing number of academics are coming on board in terms of opportunities. But if I look at our installed base and if I look at the accounts that we're closing, it's still tilted, Jason, toward the commercial, probably exactly the flip ratio, meaning about 60-40 or so tilted towards commercial. You're making an interesting point that whether it's the increased evidence and publications that's driving the academics, I think that's part of it. The other part of it is that academics need time to get grants. That's different than the commercial budget framework. So the product has been out there, the evidence has been growing, and these academics are beginning to secure the funding for the type of research needed to work with Seer. So I think that's also in part driving it. And then the comment you made about the capital constraints in terms of the commercial customers, and that is correct. I mean, clearly, the macro picture is making it difficult for CapEx purchases, especially for new technologies like Seer. That said, also the increased publications are helping us with those dialogue. And increasingly, we're seeing the size of the studies that we're having conversations with, whether it's for commercial entities or academic entities to be getting larger and larger. I mean, we're now in multiple conversations of studies that are 10,000-plus in study size. And I can tell you that about a year ago, we were having very few of those kinds of conversations. So I think that the data and the evidence are also driving larger and larger studies to become possible for us. David, do you want to add anything?

No, I think you covered it, Omid. I think that was great.

Our next question comes from the line of Dan Brennan with TD Cowen.

This is William on for Dan. First question I have is about kind of a competition question. The proteomics space is gaining a lot of attention, and there are other solutions that think to overcome the same problems as Proteograph. Just wondering how we should think about the evolution of the affinity-based proteomics market as more solutions become available? And is growing overall awareness a tailwind?

So the proteomic market, by the way, I think, is in its infancy and it's only going to grow. And the growth is going to be among the omics customer or the genomic customers that are going to begin to connect their genomic information functionally to proteomic information and get a ton more value in terms of that content. The targeted approaches scaled first, and that's because the untargeted approaches like the approach that Seer takes with the Proteograph leveraging a mass spec, those approaches were not available. And so the customer, years ago, had only the optionality to use a targeted approach if they were going to do a study of any size. Today, that dynamic is changing. I had predicted, by the way, that in 2025, the first population scale unbiased, deep unbiased proteomic study will go underway. I actually have increasing visibility for that statement to be correct. I mean, the notion of doing tens of thousands of samples, deep unbiased proteomics on a mass spec would seem like a pipe dream. Today, that is completely a reality because of the Proteograph Product Suite and because the mass specs are getting better and better. So the customers are progressively recognizing this. And I think going forward, there is going to be room for targeted approaches to exist and there's going to be a very important role for untargeted approaches to add the content in proteomics that today has not been discovered yet. I think as content is discovered more and more, there's actually the utility and a need for targeted approaches to interrogate those very specific proteins that have been discovered using unbiased approaches. So both are going to coexist. I think it's a flywheel where more and more untargeted approaches are probably going to drive more and more demand for targeted approaches. I don't see the other side working other than the fact that untargeted approaches were the first to become at scale available. But I think the way this will work is that untargeted approaches will drive content. Those content will drive value for targeted approaches to exist and then potentially new end markets would get created and existing end markets would expand because of it.

One more question I have is on the margins. Just wondering how we should think about margins exiting the year and into '25. Previously, we're targeting around 50% gross margins. Should next year see a dip in gross margins if instrument placements ramp?

I think for the back half of the year, I think we're still on track to kind of be in that area. We were 48% and I think we're trending for the nine months, I think we're around 49%, 49.5%. So I think we're going to be in that 50% area. We're not giving any guidance right now on next year, and we'll kind of give you an update and more detail on that on our year-end call at the beginning of the year. But again, we'll have more clarity around that and more color to provide you at that time.

Our next question comes from Rachel Vatnsdal with JPM.

This is Jaden Rismay on for Rachel Vatnsdal from JP Morgan. So first, maybe just to start off, how do you anticipate your recently announced collaboration with Thermo will impact Seer's market reach, customer base, and ultimately, the top line? And are there any specific customers where you expect to see the most growth as a result of this partnership?

Thank you for the question, Jaden. This is Omid. First, let me provide some context. The timing for this partnership was ideal because the value of the Proteograph has been increasingly recognized by key opinion leaders and customers. This recognition has made it easier for our partners to sell our products without needing the deep expertise from Seer. We have signed an agreement with Thermo Fisher Scientific, and there are still several implications to address for 2025. In the upcoming weeks, we will discuss how to operationalize this partnership for a launch in the first quarter. I should have a clearer idea of the expected revenue from this partnership by the time of our next call, the Q4 year-end call. The advantage of this partnership is that Thermo already has several opportunities for their Astral instrument at different stages of the sales process. For Seer, this may help us shorten the Proteograph sales cycle by leveraging existing Astral instruments that are being placed. However, it’s important to note that the typical sales cycle for capital equipment is lengthy, and I expect that will still apply to both the Astral and the Proteograph. Regarding customer benefits, those likely to engage in proteomic studies of biofluids and plasma or serum will benefit the most from the Proteograph right away. Customers focused on cells or tissue might have less motivation to use the Proteograph since the Astral performs well independently in those areas. In the case of plasma, the added value of the Proteograph is substantial. For instance, while the Astral can detect around 750 proteins in plasma, using the Proteograph can increase that to 6,000, 7,000, or even 8,000 proteins, depending on the biological sample. This added value makes it appealing to a significant portion of the Astral placements. I am very optimistic about this and pleased to be expanding our relationship with Thermo, who has been a strong partner over the past three years.

And then for my second question, I was wondering, what are you seeing from the STAC program you launched in Germany? And how is the progression of that service been so far? And any expectations for the end of the year and into '25?

So yes, we continue to see good traction, both in our US STAC as well as our EU STAC. We've seen, I think, just in the ramp-up and the operationalizing of the EU STAC. During the third quarter, we've seen good demand from those customers in Europe to be able to use our service over there. So we are very optimistic about that. And I think we'll continue to see the trend of continuing nice steady growth in terms of the service business for the fourth quarter. And then we certainly anticipate continuing that into 2025. Obviously, we can give you more thoughts on that on our year-end call. But we are pleasantly surprised with the amount of interest we've had. We are continuing to also invest strategically. So we'll do some projects at a lower cost for collaborators such that we can get data and they publish studies and publish papers. So it's actually a strategic asset for us as well as we work to get data out there quickly into the hands of our customers that want to publish and do various studies. So overall, we're very pleased with it, and I think we'll continue to see nice steady growth out of it.

I'm showing no further questions at this time. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.